Understand the asset · Business before price

Amgen AMGN

Develops, manufactures and sells biologic and other therapeutic products.

Drug development and therapeutics
How it earns money

Develops, manufactures and sells biologic and other therapeutic products.

Industry position and competition

Compare specific drugs, indications and treatment approaches; size does not establish efficacy or development success.

ETF-Investor interpretation
Operating evidence to watch

Watch trials, approvals, patents, commercialization and cash reserves; distinguish development-stage programs from established revenue.

ETF-Investor interpretation
Is the price attractive?

Use this page’s valuation panel for the current price, earnings expectations and historical position. Understand the business before judging the price; a low historical rank does not rule out falling earnings.

ETF-Investor interpretation
Competition and business comparisons
  • GILD · Gilead Sciences

    Develops and sells medicines including antiviral and oncology treatments. This is a business comparison; products and customers can differ, not every business competes directly.

  • REGN · Regeneron Pharmaceuticals

    Develops and commercializes antibody medicines and other therapies. This is a business comparison; products and customers can differ, not every business competes directly.

Sources

Reviewed 2026-10-27 · Read operating facts in their stated reporting period; use this page’s data panel for valuation.

Is AMGN expensive or cheap? How to read PE percentiles

ETF-Investor compares current PE with its own comparable historical observations to place valuation in context. A lower percentile means lower valuation relative to that sample, not a price bottom or a probability of gains.

Available history varies by asset. Forward PE percentiles require comparable forecast history. Exact values, historical windows and deeper research follow account access. PE percentile methodology

Understanding Amgen (AMGN)

Study price movements, valuation and earnings separately. A falling price does not establish fair value, and a low valuation does not guarantee returns.

TTM PE (approx.)
—
Close
438.82 USD
Year-to-date
—
From 52-week high
—
Historical valuation context
Insufficient comparable history; no assessment

Market date: 2026-11-19 · Missing observations are not invented. General research, not investment advice.

Valuation basis date: — · Valuation may be updated using a consistent earnings basis and can differ from other websites.

Which tracked ETFs hold this company?

Limited to collected holdings of tracked ETFs, not all funds. See each ETF for holdings dates.

What deserves further research?

For longer horizons, examine valuation and sustainable earnings. For medium horizons, check whether earnings expectations are supported by reported results. PE and drawdown alone do not establish a short-term trading signal.

Why can PE differ between websites?

Price dates, reported versus adjusted earnings, fiscal-year estimates and next-twelve-month estimates can differ. Align dates and earnings definitions before comparing.

Amgen · AMGN

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.